医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

More Than 400 Students of Zhangjiajie Daqiao Centre School Visited Jinchi Biotech Ltd.’s Giant Salamander Museum

2014年05月21日 AM02:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

Jinchi Biotech Ltd., Since the Giant Salamander Museum opened to the public in 2010, it has played a significant role in the science education of Zhangjiajie local schools, and it was awarded national Science Education Base. On April 11, 2014, Zhangjiajie Giant Salamander Museum welcomed more than 400 students and teachers of Zhangjiajie Daqiao Centre School. During the guided tour the students were excited to learn a great deal of interesting knowledge about giant salamanders and in the quiz session after the tour they were able to answer most of the questions correctly. This has laid a solid foundation for the promotion of giant salamander knowledge as well as giant salamanders and environment protection among the student society.

On April 2014, a total of 31,713 tourists has visited the Giant Salamander Museum (excluding VIP and group tourists), which exhibited a 40.12% increase from April 2013.

ABOUT JINCHI

www.jc-biotech.com

Owning the world’s only Giant Salamander Museum, Jinchi Biotech Ltd. mainly specializes in the R&D of giant salamander related biotech products, with more than 40 skincare and health products under two product lines, namely SHINIQUE and ANDRIAS. With strong scientific research background and a comprehensive business model, Jinchi Biotech Ltd. values virtue and goodwill, commits to deliver quality products to consumers, and devotes to the health, beauty and biomedical industries.

Disclaimer

The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表